

Appendix.

A chemical-genetic interaction map of small molecules using high-throughput imaging in cancer cells

Breinig et al.

Table of content:

Appendix Figure S1: Quality control.

Appendix Figure S2: Phenotypic features.

Appendix Figure S3: Quantitative analysis of chemical-genetic interactions across multiple phenotypic features.

Appendix Figure S4: Significant multiparametric chemical-genetic interactions.

Appendix Figure S5: Strong main effects of gene KO and associations of isogenic cell lines.

Appendix Figure S6: Synthetic lethal pharmacogenetic interactions.

Appendix Figure S7: Bendamustine and disulfiram interaction spectrum.


Appendix Figure S8: Clustering of chemical-genetic interactions.

Appendix Figure S9: Association between clustering of compounds as shown in Fig 5A and respective interaction spectra for drugs within clusters.

Appendix Figure S10: Integration of phenotypic profiling and chemical-genetic interaction mapping improves resolution.

Appendix Figure S11: Image-based chemical-genetic interaction analyses outperforms other methods.

Appendix Figure S12: The EGFR inhibitor tyrphostin AG555 impairs proteasome function.






Appendix Figure S1. Quality control.

Images showing experimental artefact, such as autofluorescence of AC-93253 iodide, were removed from the analysis.

Here, a high fluorescence background and the occurrence of fluorescent speckles (arrows) can be seen in the TRITC channel used to detect actin via Phalloidin-TRITC staining.

Image of DMSO treated cells is included as a reference, showing low fluorescence background and specific actin staining.


A**B****C**

Appendix Figure S2. Phenotypic features.

A Feature names to Figure 1C. Linear decomposition selected a final set of 20 phenotypic features.

B Feature names to Figure 1D. Phenotypic features are grouped in 5 phenotypic categories and span phenoprints.

C Feature names to Figure 2 and 4. Phenotypic interactions for the selected 20 features are grouped in 5 phenotypic categories.




Appendix Figure S3. Quantitative analysis of chemical-genetic interactions across multiple phenotypic features.

Chemical-genetic interactions were calculated for all 20 phenotypic features as described. Colchicine and BIX01294 show multiple interactions in CTNNB1 wt cells.


Phenotypic chemo-genomic interactions are shown unscaled.

Interactions are further categorized in positive and negative interactions according to the sign of interaction terms (see Material and Methods for details). * adjusted p-value < 0.01.


1,10-Phenanthroline monohydrate




2,3-Butanedione monoxime




2,3-Dimethoxy-1,4-naphthoquinone




2-Chloroadenosine




2-Chloroadenosine triphosphate tetrasodium




2-methoxyestradiol




4-Imidazolemethanol hydrochloride




4-Methylpyrazole hydrochloride




5-azacytidine




5-Bromo-2'-deoxyuridine




5-fluoro-5'-deoxyuridine




5-Fluorouracil




5'-N-Ethylcarboxamidoadenosine




5-(N-Ethyl-N-isopropyl)amiloride




5-(N,N-hexamethylene)amiloride




6-Methoxy-1,2,3,4-tetrahydro-9H-pyrido[3,4b]indole




7-Cyclopentyl-5-(4-phenoxy)phenyl-7H-pyrrolo[2,3-d]pyrimidin-4-ylamine




A-134974 dihydrochloride hydrate




A-77636 hydrochloride




ABT-702 dihydrochloride




Actinonin




Aminopterin




Ammonium pyrrolidinedithiocarbamate




Amoxapine




Amsacrine hydrochloride




(+)-AMT hydrochloride




Ancitabine hydrochloride




Anisotropine methyl bromide




ARP 101




Auranofin




Aurothioglucose




Azathioprine




Bay 11-7082




Bay 11-7085




Beclomethasone




Bendamustine hydrochloride




Benzoxathian hydrochloride




Benztropine mesylate




beta-Chloro-L-alanine hydrochloride




beta-Lapachone




Betamethasone




BIO




Bisoprolol hemifumarate salt




BIX 01294 trihydrochloride hydrate




BNTX maleate salt hydrate




Brefeldin A from Penicillium brefeldianum




Bromoacetyl alprenolol methane




(+)-Bromocryptine methanesulfonate




(+)-Brompheniramine maleate




BTO-1




Budesonide




(+)-Butaclamol hydrochloride




Caffeic acid phenethyl ester




Calcimycin




Cantharidic Acid




Cantharidin




Capsazepine




Carboplatin




Carvedioli




CB 1954




CGP 57380




CGP-74514A hydrochloride




CGS-15943




(+)-Chloro-APB hydrobromide




CHM-1 hydrate




cis-Azetidine-2,4-dicarboxylic acid




CK2 Inhibitor 2




Clemastine fumarate




Colchicine




Cyclosporin A




Cytosine-1-beta-D-arabinofuranoside hydrochloride




DAPH







(E)-5-(2-Bromovinyl)-2'-deoxyuridine




EGTA




Ellipticine




Emetine dihydrochloride hydrate




Enalaprilat dihydrate




ET-18-OCH₃




Ethopropazine hydrochloride




Etoposide







Hydralazine hydrochloride




IB-MECA




IC 261




Idarubicin




Ifenprodil tartrate




Indatraline hydrochloride












Indirubin-3'-oxime




Iodoacetamide




IRAK-1/4 Inhibitor I**Ivermectin****JL-18****L-703,606 oxalate salt hydrate****L-750,667 trihydrochloride****L-Canavanine sulfate****LFM-A13****Loperamide hydrochloride**




Mevastatin




MG 624




Mitoxantrone




(+)-MK-801 hydrogen maleate




MNS




Molsidomine





N6-2-(4-Aminophenyl)ethyladenosine




N-Acetyl-L-Cysteine









Phorbol 12-myristate 13-acetate




Pifithrin-mu




p-MPPI hydrochloride




Podophyllotoxin




Prilocaine hydrochloride




Promazine hydrochloride




Promethazine hydrochloride




Pyrocatechol







SB 415286




(S)-(+)-Camptothecin




Sivelestat sodium salt hydrate




SKF 96365




Sobuzoxane




Spiperone hydrochloride




Static




Staurosporine aglycone




SU 5416




(-)-Sulpiride




Supercinnamaldehyde




Taxol




TBBz




Terfenadine




Tetraethylthiuram disulfide




Thapsigargin




TMPH hydrochloride




Tomoxetine




Trequinsin hydrochloride




Trimipramine maleate




Tyrphostin A9




Tyrphostin AG 494




Tyrphostin AG 555




U0126




U-74389G maleate




(+)-Vesamicol hydrochloride




Vinblastine sulfate salt




Vincristine sulfate




WIN 62,577




Wortmannin from Penicillium funiculosum




Y-27632 dihydrochloride



YC-1






Appendix Figure S4. Significant multiparametric chemical-genetic interactions.

Chemical-genetic interactions were calculated for all 20 phenotypic features as described. A total of 193 compounds revealed significant interactions and their respective interaction spectra are plotted alphabetically.

Interactions are scaled from 0-1. * FDR < 0.01, highlighted in red.




Appendix Figure S5. Strong main effects of gene KO and associations of isogenic cell lines.
A Cell number for each isogenic cell line tested after 48h growth under control conditions (DMSO treatment). Particular isogenic cell lines display a pronounced phenotypic effect, i.e. impaired proliferation as compared to parental HCT116 cells.



B Unsupervised clustering of isogenic cell lines based on their 20-feature phenotype signature reveals that the parental HCT116 cell lines from two different sources cluster tightly together.

CTNNB1 wt cells and AKT1/2 KO cells cluster apart from the other cell lines, indicating that the KO of respective genes induces strong phenotypic main effects.

C Unsupervised clustering of the phenotypic chemical-genetic interaction profiles for all drugs on all 20 phenotypic features reveals that the parental HCT116 cell lines from two different sources cluster tightly together. KRAS wt cluster together with MEK1 KO and not with MEK2 KO cells, indicating the key role of MEK1 in KRAS signaling.




Appendix Figure S6. Synthetic lethal pharmacogenetic interactions.
Bendamustine specifically impaired the growth of AKT1/2 KO cells.
Disulfiram specifically impaired the growth of MEK1 KO cells.
Actin = red, DNA = cyan.

A**B**



Appendix Figure S7. Bendamustine and disulfiram interaction spectrum.

A Bendamustine interaction spectrum. Bendamustine revealed chemical-genetic interactions across multiple phenotypic features including cell number in AKT1/2 double KO cells (highlighted in red).


B Disulfiram interaction spectrum. Disulfiram revealed chemical-genetic interactions across multiple phenotypic features, including cell number in MEK1 KO cells (highlighted in red). Phenotypic chemo-genomic interactions are shown unscaled which reveals that interactions are rare. Interactions are further categorized in positive and negative interactions according to the sign of interaction terms. * adjusted p-value < 0.01.




Appendix Figure S8.
Clustering of chemical-genetic interactions.
 Unsupervised clustering based on the correlation of interaction profiles of all genetic backgrounds for 20 phenotypic features. Color coding visualizes automated cluster analysis using a 0.6 height cutoff for the cluster tree and the inclusion of >2 and <10 drugs per cluster.
 Unique drug identifiers for compounds in the LOPAC library as supplied by Sigma as well as compound names are depicted (see also Table EV1).




PD 169316 C3
SB 202190




Betamethasone C4
Beclomethasone





DMAT C5
TBBz




5'dFUrC C6
5-FU







Carboplatin C9
CB 1954




Bendamustine
Iodoacetamide
Pifithrin-mu
Parthenolide
Supercinnamaldehyde C10




Ouabain C11
Dihydro-Ouabain
Brefeldin A




CGP-74514A C12
Emetine
NSC95397




BAY 11-7082 C13
BAY 11-7085
STATTC




YC-1 C14
ARP 101




Cantharidic acid C15
Cantharidin
BIO




Phenanthroline C16
5-Azacytidine
Aminopterin
Methotrexate



Rottlerin C17
Niclosamide



Disulfiram ZPCK C18
Tyrophostin AG 555
CAPE




Appendix Figure S9. Association between clustering of compounds as shown in Fig 5A and respective interaction spectra for drugs within clusters.

While in some instances the similarity of drug profiles was a result of coordinated subtle covariation across multiple cell lines and phenotypes, in other cases it was driven by the similarity of distinctive phenotypes of individual cell lines.

For example, the CK2 inhibitors DMAT and TBBz (cluster C5) affected nuclear shape features specifically in cells with only the wildtype copy of PI3KCA (HCT116 PI3KCA wt +/ mt -).


The clustering of the compounds ARP101 and YC-1 in C15 was driven by their distinct phenotypes in cells with only the wildtype copies of CTNNB1 (HCT116 CTNNB1 wt +/ mt -) and PI3KCA (HCT116 PI3KCA wt +/ mt -).

The clustering of compounds in C18 was driven by distinctive interactions with MEK1 KO cells.




Appendix Figure S10. Integration of phenotypic profiling and chemical-genetic interaction mapping improves resolution.

Unsupervised clustering based on profile correlation using data only on cell number for all twelve genetic backgrounds screened (Genotype), using data from image-based phenotypes of one genetic background (parental HCT116; P2) (Multiparametric phenotypes), or using interaction profiles derived from both genetic backgrounds and image-based phenotypes (Genotypes and multiparametric phenotypes). Each heatmap is ordered based on individual clustering of respective datasets. Blue squares indicate compounds in cluster C4, red squares indicate compounds in cluster C18 (see Fig 5A). In contrast to the low-resolution obtained for genotype or multiparametric phenotype analysis, the combination of phenotypic profiling with chemical-genetic interaction mapping provides distinct high-resolution clusters.



Appendix Figure S11. Image-based chemical-genetic interaction analyses outperforms other methods.
A Compounds that share chemical similarity have a higher correlation of interaction profiles as compared to drugs that do not share chemical similarity, as indicated by the shift of the empirical cumulative density function (ECDF) for shared structures (red curve) compared to non-shared structures (blue curve). Genotype: data only on cell number using 12 genetic backgrounds; Multiparametric phenotypes: data using image-based phenotypes of one genetic background (parental HCT116; P2); Genotypes and multiparametric phenotypes: interaction profiles derived from both genetic backgrounds and image-based phenotypes.

B Resolution index (ΔAUC) which displays the performance with which each strategy separated drugs that share/do not chemical similarity is shown for aforementioned approaches (see methods for details).



Appendix Figure S12. The EGFR inhibitor tyrphostin AG555 impairs proteasome function. Tyrphostin AG555 increases Ubiquitin abundance. Western blots of total ubiquitin levels after 24 h treatment with compounds at a concentration of 5 μ M in HCT116 cells. Tyrphostin AG555 increases the abundance of Ubiquitin, which indicates proteasome inhibition. The proteasome inhibitors MG132 and bortezomib served as positive controls. EGFR inhibitors AG1478 and DAPH did not increase the abundance of ubiquitin. Representative example of 4 independent experiments is shown.